Consumer confidence climbed more than expected to lift the markets during the midday with the Dow adding 4 points to 14,823. Nasdaq gained 18 points to 3325.
On the upside
Pfizer (NYSE: PFE) engaged in discussions with the Food and Drug Administration for next steps in securing approval for the abuse resistant pain treatment Remoxy that was jointly developed by Pain Therapeutics (Nasdaq: PTIE) and Durect (Nasdaq: DRRX).
Transition Therapeutics (Nasdaq: TTHI) reported positive results from a clinical study of its type 2 diabetes treatment TT-401.
First quarter earnings slipped for 3D Systems (NYSE: DDD) but revenue rose to beat expectations.
On the downside
Indications that the Food and Drug Administration will require additional testing for Delcath Systems' (Nasdaq: DCTH) chemotherapy system Melblez sent shares of the medical device maker tumbling.
Newmont Mining (NYSE: NEM) reported lower first quarter earnings and revenue that fell short of analyst expectations.
First quarter earnings slipped for U. S. Silica Holdings (NYSE: SLCA).
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 3 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 index added 2 points to 1596.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here